Buscar
LivaNova PLC
LIVNAñadir a la lista de seguimiento
80.140USD
-0.910-1.12%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
4.40BCap. mercado
40.53P/E TTM
Más Datos de LivaNova PLC Compañía
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Información de LivaNova PLC
Símbolo de cotizaciónLIVN
Nombre de la empresaLivaNova PLC
Fecha de salida a bolsaOct 19, 2015
Director ejecutivoMakatsaria (Vladimir A)
Número de empleados2900
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 19
Dirección20 Eastbourne Terrace
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW2 6LG
Teléfono442033250662
Sitio Webhttps://www.livanova.com/
Símbolo de cotizaciónLIVN
Fecha de salida a bolsaOct 19, 2015
Director ejecutivoMakatsaria (Vladimir A)
Ejecutivos de LivaNova PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
44.65K
--
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
37.57K
+13.31%
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
22.19K
+42.53%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
12.62K
+28.18%
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
--
Franco Poletti ,
Franco Poletti ,
President, Cardiopulmonary Business Unit
President, Cardiopulmonary Business Unit
10.97K
+17.36%
Ms. Brooke Story
Ms. Brooke Story
Independent Director
Independent Director
9.79K
+36.33%
Mr. Francesco Bianchi
Mr. Francesco Bianchi
Independent Director
Independent Director
9.58K
+24.58%
Mr. Michael Damon Hutchinson
Mr. Michael Damon Hutchinson
Senior Vice President, Chief Legal Officer, Company Secretary
Senior Vice President, Chief Legal Officer, Company Secretary
6.80K
--
Ahmet Tezel
Ahmet Tezel
Senior Vice President, Chief Innovation Officer
Senior Vice President, Chief Innovation Officer
6.09K
+31.74%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
44.65K
--
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
37.57K
+13.31%
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
22.19K
+42.53%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
12.62K
+28.18%
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
--
Franco Poletti ,
Franco Poletti ,
President, Cardiopulmonary Business Unit
President, Cardiopulmonary Business Unit
10.97K
+17.36%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de LivaNova PLC?
Los cinco principales accionistas de LivaNova PLC son: Mr. Alex Shvartsburg
¿Cuántas instituciones poseen acciones de LivaNova PLC (LIVN)?
A fecha de 2026Q1, 609 instituciones poseen acciones de LivaNova PLC, con un valor de mercado combinado de aproximadamente 60.49M, lo que representa el 110.12% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -11258417.00.